Partnering is at the core of our business: we collaborate to unlock the potential of cutting-edge science and advance patient care. From our focused R&D engine to high-quality manufacturing and novel access approaches, we have the expertise and capabilities to bring high-value treatments to millions of people around the globe.
Susanne Kreutz, Global Head Corporate & Business Development
Our goal is to create long-lasting partnerships that generate joint value and advance patient care. Regardless of your development stage or partnering needs, reach out and we will work together to define our collaboration.
We look for areas of interest and mutual goals
We conduct diligences with flexibility and efficiency
We shape a deal that creates mutual value
We build long-term, sustainable partnerships
Adam Feire, Global Head Search & Evaluation
Michaela Dehio, Global Head Due Diligence and Operations
Guillaume Vignon, Global Head BD&L Transactions
Arne Wörn, Global Head Alliance Management
Novartis acquires Chinook Therapeutics, Inc., a Seattle, WA, based biopharmaceutical company focused on the discovery, development, and commercialization of precision medicines for kidney diseases.
Novartis acquires DTx Pharma, a San-Diego based, preclinical stage biotechnology company focused on leveraging its proprietary FALCON platform to develop siRNA therapies for neuroscience indications.
Our Corporate & Business Development team would like to hear from you.
